ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Mouse Models, Other"

  • Abstract Number: 1741 • ACR Convergence 2022

    Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model

    Leah Huey1, Kylie Koney1, Emily Vance1, Chia-Feng Tsai2, Rosalie K. Chu2, Marina A. Gritsenko2, Ellen Lee1, Holly Rosenzweig1 and Ruth Napier1, 1Oregon Health & Science University and VA Portland Health Care System, Portland, OR, 2Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA

    Background/Purpose: Mutations in the microbial signaling molecule NOD2 cause granulomatous uveitis, arthritis, and dermatitis in Blau Syndrome. We previously showed a novel role for Nod2…
  • Abstract Number: 1883 • ACR Convergence 2022

    Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype

    Shane Bruckner1, Kassidy Banford2, hannah Bulgart2, Kevin mcElhanon3, Rohit Aggarwal4, Chester Oddis5, Noah Weisleder1 and Wael Jarjour1, 1The Ohio State University, Columbus, OH, 2The Ohio State University Wexner Medical Center, Columbus, OH, 3Pfizer Inc., Cambridge, MA, 4Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of disorders in which autoimmune responses produce a chronic state of inflammation resulting in degeneration of skeletal…
  • Abstract Number: 2021 • ACR Convergence 2022

    Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome

    Xiaomei Shan1, Clara Reichardt1, Jeeshan Singh1, Anne Zeitler2, Christine Schauer1, Jasmin Knopf1, Martin Herrmann1, Gerhard Grossmayer1, Georg Schett1 and Luis Munoz1, 1Universitätsklinikum Erlangen, Erlangen, Germany, 2Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany

    Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands including salivary and lacrimal glands that leads to dry eyes and mouth…
  • Abstract Number: 2263 • ACR Convergence 2022

    Nanotherapeutic Approaches for the Treatment of Post-traumatic Osteoarthritis

    Luke Springer1, Kelsey Collins2, Huimin Yan2, Ying Hu3, Farshid Guilak2, Samuel Wickline4, Hua Pan2 and Christine Pham2, 1Washington University School of Medicine, St. Louis, MO, 2Washington University School of Medicine, Saint Louis, MO, 3Washington University, Saint Louis, MO, 4University of South Florida, Tampa, FL

    Background/Purpose: Osteoarthritis (OA) represents the most common form of arthritis and is a major cause of morbidity in the aging population. Post-traumatic OA (PTOA) is…
  • Abstract Number: 1478 • ACR Convergence 2021

    An Orphan Receptor and Osteoarthritis: Mouse Gpr34 Expression in Dorsal Root Ganglia After Partial Meniscectomy

    David Thomas1, Terese Geraghty2, Alia Obeidat2, Jun Li2, Rachel Miller2 and Anne-Marie Malfait3, 1University of Minnesota Internal Medicine Residency, St. Paul, MN, 2Rush University Medical Center, Chicago, IL, 3Rush University, Chicago, IL

    Background/Purpose: Osteoarthritis (OA) is one of the leading causes of musculoskeletal pain and disability. Worldwide, an estimated 303 million patients have clinically diagnosed OA, with…
  • Abstract Number: 1513 • ACR Convergence 2021

    Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors

    Ryosuke Hiwa1, Hailyn Nielsen1, James Mueller1 and Julie Zikherman2, 1University of California San Francisco, San Francisco, CA, 2UCSF Medical Center, San Francisco, CA

    Background/Purpose: Current therapies for autoimmune disease often lead to treatment-limiting immunosuppression. Selective manipulation of antigen (Ag)-specific immune responses could enhance our therapeutic approach. Targeting members…
  • Abstract Number: 0173 • ACR Convergence 2020

    mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice

    Zhengping Huang1, Ying Li2, Alexandra Wactor3, Peter Nigrovic4 and Pui Lee5, 11.Guangdong Second Provincial General Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, BOSTON, MA, 21.Brandeis University;2.Brigham and Women's Hospital, Waltham, MA, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, 51.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is potentially life-threatening disease characterized by prolonged fever, systemic inflammation and skin rash in addition to joint inflammation. Aberrant…
  • Abstract Number: 0469 • ACR Convergence 2020

    IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome

    Denny Gao1, Maggie Henderlight1, Christopher Woods1, Alexei Grom1, Sherry Thornton1, Michael Jordan1, Katheryn Wikenheiser-Brokamp1 and Grant Schulert2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening cytokine storm syndrome frequently complicating systemic juvenile idiopathic arthritis (SJIA) and driven by IFNγ. MAS is also…
  • Abstract Number: 0703 • ACR Convergence 2020

    Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect

    Francis Berenbaum1, Coralie Meurot2, Laure Sudre3, Keren Bismuth2, Revital Rattenbach2, Patrice Denefle2, Celine Martin2 and Claire Jacques3, 1AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, 2Campus Institut Pasteur Lille, 4P Pharma, Lille, France, 3Inserm, UMR_S938, Hospital Saint-Antoine, Paris, France

    Background/Purpose: Osteoarthritis (OA) is an age-related joint disease affecting millions of individuals worldwide and associated with an extremely high burden largely attributable to disability. To…
  • Abstract Number: 1077 • ACR Convergence 2020

    Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis

    Mari Kamiya1, Seon Uk Kim2, Jeong Yeon Kim3, Shinsuke Yasuda4, Eun Young Lee5 and Fumitaka Mizoguchi1, 1Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Jongno-gu, Seoul, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 4Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

    Background/Purpose: Glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM). However, the treatment with GC causes GC-induced myopathy, which further deteriorates the muscle…
  • Abstract Number: 1401 • ACR Convergence 2020

    Disease Mutation That Weakens ZAP70 Autoinhibition Enhances Responses to Weak and Self Ligands

    Lin Shen1, Mehrdad Matloubian1, Theresa Kadlecek2 and Arthur Weiss1, 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco

    Background/Purpose: ZAP70, a cytoplasmic protein tyrosine kinase, is critical for TCR signaling and T cell development. Complete loss of function of ZAP70 in humans causes…
  • Abstract Number: 1575 • ACR Convergence 2020

    CD6 Is a Target for Cancer Immunotherapy

    Jeffrey Ruth1, Mikel Gurrea Rubio2, Kalana Athukorala3, Stephanie Rasmussen1, Weber Daniel1, Peggy Randon1, M Asif Amin1, Phillip Campbell1, Pei-suen Tsou1, Yang Mao-Draayer1, Qi Wu4, Matthew Lind1, Rosemary Gedert1, Thomas Lanigan1, Venkateshwar Keshamouni1, Nora Singer5, Feng Lin6 and David Fox7, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Canton, MI, 3University of Michigan, Ann Arbor, MN, 4University of Michigan, Ann Arbor, 5The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, 6Cleveland Clinic Foundation, Cleveland, OH, 7Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…
  • Abstract Number: 1905 • ACR Convergence 2020

    Soluble Guanylate Cyclase Reduced the Gastrointestinal Fibrosis in Bleomycin-induced Mouse Model of Systemic Sclerosis

    Yuzuru Yamamoto1, Takaichi Okano2, Takumi Nagamoto2, Yoshikazu Fujikawa3, Yoshihide Ichise2, Hirotaka Yamada2, Ikuko Naka2, Yo Ueda4, Kengo Akashi5, Sho Sendo6, Akira Onishi5, Jun Saegusa7 and Akio Morinobu5, 1Kobe University, Kobe-city, Japan, 2Kobe University, Kobe, Japan, 3Kobe University, Kobe city, Japan, 4Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, 5Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, 6Kobe University, Kobe, 7Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undermined, SSc is characterized by fibrosis and…
  • Abstract Number: 1912 • ACR Convergence 2020

    Novel Role of Thy-1 (CD90) in the Pathogenesis of Skin Fibrosis

    Roberta Goncalves Marangoni1, Stacey Duemmel2, Marc Nuzzo2, Ananta Paine1, Christopher Ritchlin3 and Benjamin Korman3, 1University of Rochester Medical Center, Rochester, NY, 2Department of Medicine, University of Rochester Medical Center, Rochester, 3Department of Medicine, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Thy-1 (CD90) is a GPI-anchored cell surface protein that is highly expressed in subsets of fibroblasts. Previous work has shown that Thy-1 deficiency exacerbates…
  • Abstract Number: 1916 • ACR Convergence 2020

    KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model

    Marta Del Rio Oliva1, Michael Basler1, Darrin Bomba2, Diana Lam2, Jennifer Brandl2, Christopher Kirk2 and Marcus Groettrup1, 1University of Konstanz, Konstanz, Germany, 2Kezar Life Sciences, Inc, San Francisco, CA

    Background/Purpose: Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles and resulting in muscle weakness. PM is a rare disease, and there are…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology